188 related articles for article (PubMed ID: 37004644)
1. Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.
Nguyen CN; Iyer SP; Duvic M; Barde PJ; Nair A; Routhu KV; Huen AO
Invest New Drugs; 2023 Apr; 41(2):350-355. PubMed ID: 37004644
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
3. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
Janiga J; Kentley J; Nabhan C; Abdulla F
Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
[TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
6. Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.
Martinez-Escala ME; Kuzel TM; Kaplan JB; Petrich A; Nardone B; Rosen ST; Guitart J
JAMA Oncol; 2016 Jun; 2(6):790-3. PubMed ID: 27054291
[TBL] [Abstract][Full Text] [Related]
7. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
[TBL] [Abstract][Full Text] [Related]
8. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
Quadri I; Reneau JC; Hanel W; Chung CG
Front Immunol; 2023; 14():1291259. PubMed ID: 38022633
[TBL] [Abstract][Full Text] [Related]
9. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
Reddy SA
Crit Rev Oncol Hematol; 2016 Oct; 106():99-107. PubMed ID: 27637355
[TBL] [Abstract][Full Text] [Related]
10. Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma.
Trager MH; Geskin LJ
G Ital Dermatol Venereol; 2019 Dec; 154(6):681-695. PubMed ID: 31859467
[TBL] [Abstract][Full Text] [Related]
11. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
Ramelyte E; Dummer R; Guenova E
Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
[No Abstract] [Full Text] [Related]
12. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
[TBL] [Abstract][Full Text] [Related]
13. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
[TBL] [Abstract][Full Text] [Related]
14. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
[TBL] [Abstract][Full Text] [Related]
15. New nonchemotherapy treatment options for cutaneous T-cell lymphomas.
Xu S; Foss F
Expert Rev Anticancer Ther; 2021 Sep; 21(9):1017-1028. PubMed ID: 33554707
[TBL] [Abstract][Full Text] [Related]
16. SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL.
Brazel D; Pinter-Brown L
Clin Lymphoma Myeloma Leuk; 2023 Jun; 23(6):401-409. PubMed ID: 37061415
[TBL] [Abstract][Full Text] [Related]
17. Mycosis fungoides and Sézary syndrome.
Jonak C; Tittes J; Brunner PM; Guenova E
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
[TBL] [Abstract][Full Text] [Related]
18. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
Lewis DJ; Rook AH
Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.
Iyer SP; Huen A; Ai WZ; Jagadeesh D; Lechowicz MJ; Okada C; Feldman TA; Ghione P; Alderuccio JP; Champion R; Kim SH; Mohrbacher A; Routhu KV; Barde P; Nair AM; Haverkos BM
Haematologica; 2024 Jan; 109(1):209-219. PubMed ID: 37439343
[TBL] [Abstract][Full Text] [Related]
20. Alitretinoin in the treatment of cutaneous T-cell lymphoma.
Kaemmerer T; Stadler PC; Helene Frommherz L; Guertler A; Einar French L; Reinholz M
Cancer Med; 2021 Oct; 10(20):7071-7078. PubMed ID: 34435474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]